---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: PAD - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/pad
version: v1
---

# PAD - NCI

# PAD

This combination contains the chemotherapy drugs bortezomib (PS-341) and doxorubicin hydrochloride (Adriamycin)
and the steroid hormone dexamethasone. Combinations usually work better than single drugs because
different drugs kill
cancer
cells in different ways.

Drugs in the PAD combination:

|  |  |
| --- | --- |
| **P** | = [Bortezomib](/about-cancer/treatment/drugs/bortezomib) (PS-341) |
| **A** | = [Doxorubicin Hydrochloride](/about-cancer/treatment/drugs/doxorubicinhydrochloride) (Adriamycin) |
| **D** | = [Dexamethasone](/about-cancer/treatment/drugs/dexamethasone) |

Each of the drugs in this combination is approved by the
[Food and Drug
Administration (FDA)](/Common/PopUps/popDefinition.aspx?id=454785&version=Patient&language=English)
to treat cancer or conditions related to cancer.

## Use in Cancer

PAD
is used to treat:

- **[Multiple myeloma](/Common/PopUps/popDefinition.aspx?id=45793&version=Patient&language=English).**

This combination may also be used with other drugs or
treatments or to treat other types of cancer.

## More About PAD

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/759138) - Detailed scientific definition and other names for this drug.
